Cytokinetics, Inc. : Cytokinetics Announces Grant From Families with Spinal Muscular Atrophy for Preclinical Development of

 Cytokinetics, Inc. : Cytokinetics Announces Grant From Families with Spinal
          Muscular Atrophy for Preclinical Development of Tirasemtiv

Award to Support Testing of Tirasemtiv in Mouse Models of Spinal Muscular

South San  Francisco,  CA,  and  Elk  Grove  Village,  IL,  April  4,  2013  - 
Cytokinetics, Incorporated  (Nasdaq: CYTK)  and  Families of  Spinal  Muscular 
Atrophy (FSMA) announced  the award of  a grant from  FSMA to Cytokinetics  to 
support preclinical research  on muscle function  in a mouse  model of  spinal 
muscular atrophy (SMA) to be conducted with the company's fast skeletal muscle
troponin activator,  tirasemtiv.  Financial details  of  the grant  were  not 

Tirasemtiv,  the  lead  drug  candidate  from  Cytokinetics'  skeletal  muscle 
contractility program, selectively activates the fast skeletal muscle troponin
complex by increasing its sensitivity to calcium, thereby increasing  skeletal 
muscle force in response to neuronal input and delaying the onset and reducing
the degree  of muscle  fatigue.  Cytokinetics is  evaluating tirasemtiv  as  a 
potential treatment  for amyotrophic  lateral sclerosis  (ALS) in  BENEFIT-ALS 
(Blinded Evaluation of Neuromuscular  Effects and Functional Improvement  with 
Tirasemtiv in ALS),  an international  Phase IIb  clinical trial  that is  now 
enrolling patients. 

The objective of this  new funded preclinical research  is to examine  whether 
tirasemtiv can improve muscle function  in mouse models of SMA.  Cytokinetics 
will examine the effects of tirasemtiv on leg and respiratory muscle  function 
and the effects of  tirasemtiv to reduce fatigue  and improve muscle  strength 
during exercise.

"There remains a significant unmet medical  need for a novel therapy that  can 
improve muscle function,  including respiratory muscle  function, in  patients 
with SMA," stated Jill Jarecki, Ph.D., Research Director of Families of Spinal
Muscular Atrophy. "If tirasemtiv can improve muscle function in mouse  models 
of SMA,  it may  also ameliorate  muscle  weakness in  patients with  SMA  and 
thereby has the potential to improve quality of life for patients affected  by 
this disease."

"We are pleased to  be the recipient  of this grant  funding from Families  of 
Spinal Muscular Atrophy which will enable  us to investigate the potential  of 
tirasemtiv to  address some  of the  unmet needs  of this  grievous  disease," 
stated Jeffrey Jasper,  Ph.D., Cytokinetics' Head  of Pharmacology. "We  look 
forward to working with Families of Spinal Muscular Atrophy on this  important 
project which may inform Cytokinetics'  plans for future clinical  development 
activities of tirasemtiv." 

Development Status of Tirasemtiv

Tirasemtiv (formerly CK-2017357) is currently being evaluated in  BENEFIT-ALS, 
an international,  double-blind,  randomized,  placebo-controlled,  Phase  IIb 
clinical trial designed  to evaluate  the safety,  tolerability and  potential 
efficacy of this novel  drug candidate in patients  with ALS. BENEFIT-ALS  is 
designed to enroll approximately 400 patients who will first complete one week
of treatment  with open-label  tirasemtiv  at 125  mg twice  daily.  Following 
completion of the open-label period, patients will be randomized to receive 12
weeks of  double-blind  treatment with  twice-daily  oral ascending  doses  of 
tirasemtiv beginning at 125 mg twice daily and increasing weekly up to 250  mg 
twice daily or a dummy dose titration with placebo. Clinical assessments  will 
take place  monthly  during  the  course  of  treatment;  patients  will  also 
participate in  follow-up evaluations  one and  four weeks  after their  final 
dose. The  primary efficacy  analysis  of BENEFIT-ALS  will compare  the  mean 
change from baseline in  the ALS Functional Rating  Scale in its revised  form 
(ALSFRS-R) on  tirasemtiv versus  placebo.  Secondary endpoints  will  include 
Maximum Voluntary  Ventilation (MVV)  and other  measures of  respiratory  and 
skeletal muscle function. Patients taking  riluzole at the time of  enrollment 
and who  are randomized  to  receive tirasemtiv  will  receive riluzole  at  a 
reduced dose of 50 mg daily. Cytokinetics plans to conduct BENEFIT-ALS in over
70 sites across the United States, Canada, and several European countries.

Data from prior Phase IIa clinical  trials of tirasemtiv in patients with  ALS 
were presented at the  2012 American Academy of  Neurology Annual Meeting  and 
the 2010 International Symposium on ALS and Motor Neurone Diseases.

About Families of Spinal Muscular Atrophy 

Families of Spinal Muscular Atrophy is the world's leader focused on funding
SMA research to develop a treatment and cure for the disease. The successful
results and progress that the organization has delivered, from basic research
to drug discovery to clinical trials, provide real hope for families and
patients impacted by the disease. The charity has invested over $55 million in
research and has been involved in funding half of all the ongoing novel drug
programs for SMA. Families of SMA is a nonprofit 501(c)3 organization, with 31
Chapters and 90,000 members and supporters throughout the United States. The
organization's work has produced major discoveries, including identification
of the underlying cause and a back-up gene for the disease, which provides a
clearly defined target for disease altering therapies. The organization is
also dedicated to supporting SMA families through networking, information and
services and to improving care for all SMA patients.

About Cytokinetics

Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function for the  potential treatment of  serious diseases and  medical 
conditions.  Cytokinetics'  lead  drug  candidate  from  its  cardiac   muscle 
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment  of heart failure. Amgen  Inc. holds an  exclusive 
license worldwide  (excluding Japan)  to develop  and commercialize  omecamtiv 
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization  participation  rights.  Cytokinetics  is  independently 
developing tirasemtiv and CK-2127107, both fast skeletal muscle activators, as
potential treatments  for  diseases  and medical  conditions  associated  with 
aging, muscle wasting  or neuromuscular dysfunction.  Tirasemtiv is  currently 
the subject of a Phase II clinical trials program and has been granted  orphan 
drug  designation  and  fast   track  status  by  the   U.S.  Food  and   Drug 
Administration and  orphan  medicinal  product  designation  by  the  European 
Medicines Agency for the potential treatment of amyotrophic lateral sclerosis,
a debilitating disease  of neuromuscular  impairment in  which treatment  with 
tirasemtiv produced potentially clinically relevant pharmacodynamic effects in
Phase II trials. All of these  drug candidates have arisen from  Cytokinetics' 
muscle biology  focused  research  activities and  are  directed  towards  the 
cytoskeleton. The  cytoskeleton is  a complex  biological infrastructure  that 
plays a fundamental role within every human cell. Additional information about
Cytokinetics can be obtained at

This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  Safe  Harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements  relating  to   Cytokinetics'  and  its   partners'  research   and 
development activities,  including the  conduct of  preclinical research,  the 
conduct, design and results of  clinical trials, the significance and  utility 
of clinical  trial  results, and  the  properties and  potential  benefits  of 
tirasemtiv and Cytokinetics'  other drug candidates,  including the  potential 
utility of tirasemtiv  as a  treatment of SMA.  Such statements  are based  on 
management's current expectations,  but actual results  may differ  materially 
due to  various  risks  and  uncertainties, including,  but  not  limited  to, 
Cytokinetics anticipates that  it will  be required  to conduct  at least  one 
confirmatory Phase III clinical trial of tirasemtiv in ALS patients which will
require significant additional funding,  and it may be  unable to obtain  such 
additional funding on acceptable terms,  if at all; potential difficulties  or 
delays  in   the  development,   testing,  regulatory   approvals  for   trial 
commencement, progression or product sale  or manufacturing, or production  of 
Cytokinetics' drug candidates that could slow or prevent clinical  development 
or product approval, including risks that current and past results of clinical
trials or preclinical studies may not be indicative of future clinical  trials 
results, patient enrollment for or conduct of clinical trials may be difficult
or delayed, Cytokinetics'  drug candidates  may have adverse  side effects  or 
inadequate therapeutic  efficacy, the  U.S. Food  and Drug  Administration  or 
foreign regulatory agencies may delay or limit Cytokinetics' or its  partners' 
ability to conduct clinical trials, and  Cytokinetics may be unable to  obtain 
or maintain patent or trade  secret protection for its intellectual  property; 
Amgen's decisions with respect to the design, initiation, conduct, timing  and 
continuation of development  activities for  omecamtiv mecarbil;  Cytokinetics 
may incur unanticipated research and development and other costs or be  unable 
to obtain  additional  financing  necessary  to  conduct  development  of  its 
products; Cytokinetics  may  be  unable to  enter  into  future  collaboration 
agreements for its  drug candidates and  programs on acceptable  terms, if  at 
all; standards of  care may  change, rendering  Cytokinetics' drug  candidates 
obsolete; competitive products  or alternative therapies  may be developed  by 
others for  the treatment  of indications  Cytokinetics' drug  candidates  and 
potential drug candidates may target; and risks and uncertainties relating  to 
the timing and receipt of payments from its partners, including milestones and
royalties on future potential product sales under Cytokinetics'  collaboration 
agreements with such  partners. For  further information  regarding these  and 
other risks  related  to  Cytokinetics'  business,  investors  should  consult 
Cytokinetics' filings with the Securities and Exchange Commission.

Joanna L. Goldstein
Manager, Corporate Communications & Marketing
(650) 624-3000


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.